Compare SIEB & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIEB | NOTV |
|---|---|---|
| Founded | 1886 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.6M | 29.9M |
| IPO Year | N/A | 1997 |
| Metric | SIEB | NOTV |
|---|---|---|
| Price | $3.79 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 23.4K | ★ 1.6M |
| Earning Date | 11-12-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | $90,289,000.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | N/A | $45.49 |
| P/E Ratio | $21.39 | ★ N/A |
| Revenue Growth | ★ 8.32 | 4.54 |
| 52 Week Low | $2.08 | $0.66 |
| 52 Week High | $5.77 | $6.48 |
| Indicator | SIEB | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 72.02 | 35.16 |
| Support Level | $2.82 | $0.79 |
| Resistance Level | $3.05 | $0.86 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 90.57 | 3.93 |
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.